The story of the erectile dysfunction drug presents a complex picture for investors. While the initial introduction generated massive gains, the lapse of its intellectual property protection opened the avenue to generic alternatives, dramatically eroding revenue. This creates a specific challenge for firms relying on related blockbuster offerings,

The history of Viagra, and its parent company copyright, presents a challenging case study for investors. At first a blockbuster drug, yielding billions in income, its patent expiration created a wave of knock-off medications, significantly diminishing its dominance. While some firms may try to capitalize on male sexual dysfunction, the current lan